Drug Profile
Research programme: cedar pollen allergy immunotherapy - REGiMMUNE
Alternative Names: RGI-1001Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator REGiMMUNE
- Class Antigens
- Mechanism of Action Immunomodulators; Natural killer T cell modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Allergic rhinitis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Allergic-rhinitis in Japan
- 28 Feb 2014 REGiMMUNE's cedar pollen allergy immunotherapy programme is available for licensing in World (excluding Japan) as of 28 Feb 2014. http://www.regimmune.com/
- 18 Jul 2011 Preclinical development is ongoing in Japan